Loading...
•
Jun 30, 2022
Royalty Pharma Q2 2022 Earnings Report
Royalty Pharma reported financial results and raised full-year 2022 guidance for Adjusted Cash Receipts.
Key Takeaways
Royalty Pharma reported a decrease in total income and other revenues by 3% to $536 million. However, Adjusted Cash Receipts increased by 10% to $524 million, driven by the cystic fibrosis franchise, Xtandi, and Tremfya. The company also announced transactions of up to $2.5 billion year-to-date and raised full-year 2022 guidance for Adjusted Cash Receipts to $2,275 to $2,350 million.
Net cash provided by operating activities increased 8% to $575 million.
Adjusted Cash Receipts increased 10% to $524 million, driven by a double-digit increase in royalties from the cystic fibrosis franchise, Xtandi and the addition of Tremfya.
Adjusted EBITDA grew 10% to $480 million, driven by strong growth in Adjusted Cash Receipts.
Adjusted Cash Flow increased 12% to $482 million.
Royalty Pharma
Royalty Pharma
Royalty Pharma Revenue by Segment
Revenue by Segment
Cystic Fibrosis Franchise Revenue
CapyFin.comTysabri Revenue
CapyFin.comEvrysdi Revenue
CapyFin.comXtandi Revenue
CapyFin.comImbruvica Revenue
CapyFin.comPromacta Revenue
CapyFin.comTremfya Revenue
CapyFin.comCabometyx/Cometriq Revenue
CapyFin.comTrodelvy Revenue
CapyFin.comErleada Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Royalty Pharma anticipates full-year 2022 Adjusted Cash Receipts to be between $2,275 million and $2,350 million (+7% to 10% year/year), excluding transactions announced subsequent to the date of this release.
Challenges Ahead
- Guidance reflects an estimated foreign exchange impact of approximately -3% to -4% (-$65 million to -$85 million) for full-year 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income